Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid Tumors


Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.

Cancer Network spoke with Adi Diab, MD, of The University of Texas MD Anderson Cancer Center, regarding the results of the phase I/II PIVOT-02 trial. He and fellow investigators are exploring the association between baseline tumor immune signatures and response to bempegaldesleukin (NKTR-214) and nivolumab in patients with advanced solid tumors. The results (abstract 2623) were presented at ASCO 2019.

Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content